{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:59:41Z","timestamp":1760403581242,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ijantimicag.2022.106682","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T12:21:33Z","timestamp":1666354893000},"page":"106682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus"],"prefix":"10.1016","volume":"60","author":[{"given":"Yu-Shan","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-7721","authenticated-orcid":false,"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ching","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-0836","authenticated-orcid":false,"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2022.106682_bib0001","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"year":"2020","series-title":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","key":"10.1016\/j.ijantimicag.2022.106682_sbref0002"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0003","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/01.aids.0000218550.85081.59","article-title":"Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy","volume":"20","author":"Matthews","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0004","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","article-title":"Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0005","doi-asserted-by":"crossref","first-page":"14598","DOI":"10.3748\/wjg.v20.i40.14598","article-title":"Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review","volume":"20","author":"Sun","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0007","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1097\/QAD.0000000000000347","article-title":"Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up","volume":"28","author":"Nishijima","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0000000000002589","article-title":"Efficacy and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide as maintenance treatment in HIV\/HBV-coinfected patients","volume":"86","author":"Huang","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0009","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2016.12.012","article-title":"Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro","volume":"139","author":"Liu","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0011","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cgh.2021.04.045","article-title":"Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate","volume":"20","author":"Byun","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0012","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","author":"Ogawa","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmii.2019.10.005","article-title":"Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan","volume":"54","author":"Lin","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0014","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/bioinformatics\/17.12.1244","article-title":"MEGA2: molecular evolutionary genetics analysis software","volume":"17","author":"Kumar","year":"2001","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169228","article-title":"Virological response to tenofovir disoproxil fumarate in HIV-positive patients with lamivudine-resistant hepatitis B virus coinfection in an area hyperendemic for hepatitis B virus infection","volume":"11","author":"Huang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2016.08.008","article-title":"Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)\/TDF in lamivudine resistant hepatitis B: a 5-year randomised study","volume":"66","author":"Fung","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0017","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/QAD.0000000000001744","article-title":"Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide","volume":"32","author":"Podany","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0018","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0168-8278(18)30392-1","article-title":"Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use","volume":"68","author":"Gane","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0019","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","article-title":"An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia","volume":"55","author":"Charlton","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0020","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/hep.27182","article-title":"Persistent viremia in human immunodeficiency virus\/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications","volume":"60","author":"Boyd","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0021","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/cid\/cit002","article-title":"Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus","volume":"56","author":"Matthews","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jvh.12613","article-title":"No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment","volume":"24","author":"Liu","year":"2017","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01064-18","article-title":"No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection","volume":"62","author":"Cathcart","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0024","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u00a0weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2022.106682_bib0025","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/S0168-8278(03)00312-X","article-title":"Hepatitis B virus resistance to antivirals: clinical implications and management","volume":"39","author":"Zoulim","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ijid.2017.06.016","article-title":"A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice","volume":"62","author":"Geng","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0027","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"Wang","year":"2018","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0028","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/hep.30788","article-title":"Baseline level of hepatitis B core antibody predicts spontaneous hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive children with a normal alanine aminotransferase level","volume":"70","author":"Chen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0029","doi-asserted-by":"crossref","unstructured":"Avihingsanon A, Lu H, Leong CL, Hung CC, Koening E, Kiertiburanakul S, et\u00a0al. Week 48 results of a phase 3 randomized controlled trial of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) vs dolutegravir\u00a0+\u00a0emtricitabine\/tenofovir disoproxil fumarate (DTG+F\/TDF) as initial treatment in HIV\/HBV-coinfected adults (ALLIANCE). The 24th International AIDS Conference, 2022, Oral Abstract OALBX0105.","DOI":"10.1016\/S0016-5085(23)03881-7"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12072-019-09998-5","article-title":"Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B","volume":"14","author":"Mak","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0031","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jhep.2012.01.005","article-title":"Decreased infectivity of nucleoside analogs-resistant hepatitis B virus mutants","volume":"56","author":"Billioud","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0032","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0033","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12072-019-09953-4","article-title":"Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection","volume":"13","author":"Huang","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ijantimicag.2022.106682_bib0034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/jvh.13212","article-title":"Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV\/HBV co-infected Chinese","volume":"27","author":"Yang","year":"2020","journal-title":"J Viral Hepat"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922002096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857922002096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:43:49Z","timestamp":1760377429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857922002096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":34,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0924857922002096"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106682","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106682"}}